1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  3. PPAR

PPAR

Peroxisome proliferator-activated receptors

PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-122235
    MRL-24
    Agonist 99.58%
    MRL-24 is a PPARγ agonist. MRL-24 can be used in metabolic disease related research.
    MRL-24
  • HY-111140
    YS121
    Activator 99.74%
    YS121 is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1; IC50 = 3.4 μM) and 5-lipoxygenase (5-LOX; IC50 = 6.5 μM). YS121 exhibits direct, reversible, and specific binding to mPGES-1 (KD = 10-14 μM). YS121 dose-dependently reduces PGE2 production with an EC50 of 12 μM in IL-1β-stimulated A549 cells. YS121 (compound 9) activates PPAR-α and -γ (EC50 = 1 and 3.6 μM, respectively). YS121 exhibits anti-inflammatory efficiency in human whole blood as well as in vivo. YS121 can be used for pleurisy research.
    YS121
  • HY-B0287R
    Clofibrate (Standard)
    Agonist
    Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ~500 μM for murine PPARα and PPARγ, and 55 μM, ~500 μM for human PPARα and PPARγ, respectively.
    Clofibrate (Standard)
  • HY-121538A
    CUDA disodium
    Activator
    CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease.
    CUDA disodium
  • HY-111254
    GQ-16
    Modulator 98.88%
    GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of PPARγ, exhibiting a Ki of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain.
    GQ-16
  • HY-16421
    Ragaglitazar
    Agonist 99.24%
    Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.
    Ragaglitazar
  • HY-119966
    CCT036477
    Inhibitor 99.42%
    CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2).
    CCT036477
  • HY-159944
    PPARγ agonist 14
    Agonist 98.0%
    PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases.
    PPARγ agonist 14
  • HY-146480
    PPARγ agonist 5
    Agonist 98.59%
    PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases.
    PPARγ agonist 5
  • HY-148694
    ISX-3
    Activator 99.68%
    ISX-3 is a potent anti-adipogenic and pro-osteogenic agent. ISX-3 increases the expression of PPARγ. ISX-3 has the potential for the research of osteopenia and osteoporosis.
    ISX-3
  • HY-17356S
    Fenofibrate-d6
    Agonist 99.70%
    Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate-d<sub>6</sub>
  • HY-163547
    PPAR agonist 5
    Agonist
    PPAR agonist 5 (compound 4b) is a potent PPAR agonist with EC50 values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect.
    PPAR agonist 5
  • HY-150308
    SR10221
    Inhibitor 98.96%
    SR10221, a noncovalent inverse agonist of PPARγ, represses downstream PPARγ target genes leading to growth inhibition in bladder cancer cell lines.
    SR10221
  • HY-147705
    PPARγ phosphorylation inhibitor 1
    Inhibitor 99.81%
    PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binder with the IC50 of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC50 of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects.
    PPARγ phosphorylation inhibitor 1
  • HY-W015026
    Isobutylparaben
    Agonist 98.87%
    Isobutylparaben (Isobutyl 4-hydroxybenzoate) is the agonist for PXR, CAR and PPAR. Isobutylparaben has a broad-spectrum antimicrobial activity and widely used in personal care products and cosmetics.
    Isobutylparaben
  • HY-N2303
    Eriocalyxin B
    Inhibitor 99.93%
    Eriocalyxin B is a diterpenoid compound that can be isolated from Chinese herb Isodon eriocalyx. Eriocalyxin B exhibits multiple activities, such as anti-cancer, anti-inflammatory, and inhibition of adipogenesis. Eriocalyxin B is capable of inducing apoptosis and autophagy in tumor cells. Eriocalyxin B can be used in the research of cancers, autoimmune diseases, and other conditions.
    Eriocalyxin B
  • HY-13956S1
    Pioglitazone-d4 (alkyl)
    Activator 98.55%
    Pioglitazone-d4 (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
    Pioglitazone-d<sub>4</sub> (alkyl)
  • HY-W011309A
    1-O-Hexadecyl-sn-glycerol
    Control 99.91%
    1-O-Hexadecyl-sn-glycerol [(S)-HXDG] is an alkyl glycerol monoether derived from T. aurantia.
    1-O-Hexadecyl-sn-glycerol
  • HY-130479
    AdipoR agonist 1
    Activator ≥98.0%
    AdipoR agonist 1 (Compound 112254) is an agonist for adiponectin receptor (AdipoR), which activates the transcriptional regulators like peroxisome proliferator-activated receptors (PPARs), peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), sirtuin 1 (SIRT1), and adenylate-activated protein kinase (AMPK). AdipoR agonist 1 is utilized in preventive doping research.
    AdipoR agonist 1
  • HY-107542S2
    Oleoylethanolamide-d2
    Agonist ≥98.0%
    Oleoylethanolamide-d2 is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
    Oleoylethanolamide-d<sub>2</sub>
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.